Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | P2RX3 | P56373 | 3/20 | 0.33 |
| ▸ | P2RX2 | Q9UBL9 | 3/20 | 0.33 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.32 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.30 |
| ▸ | AGBL2 | Q5U5Z8 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22871210 | 0.86 | KMT2A (0.32) | KMT2AP2RX3P2RX2S1PR1S1PR3 | |
| SCHEMBL22193246 | 0.81 | CRHR1 (0.40) | KMT2AS1PR1S1PR3MEN1MAPK1 | |
| SCHEMBL469180 | 0.81 | AGBL2 (0.32) | AGBL2 | |
| SCHEMBL19965685 | 0.81 | AGBL2 (0.32) | AGBL2 | |
| SCHEMBL21139639 | 0.81 | KMT2A (0.36) | KMT2AP2RX3P2RX2S1PR1S1PR3 | |
| SCHEMBL10192289 | 0.78 | KMT2A (0.56) | KMT2AMEN1MAPK1RAB9ASMN1; SMN2 | |
| SCHEMBL29441178 | 0.78 | KMT2A (0.35) | KMT2AP2RX3P2RX2S1PR1S1PR3 | |
| SCHEMBL17823946 | 0.78 | KMT2A (0.35) | KMT2AP2RX3P2RX2S1PR1S1PR3 | |
| Ammonia Solution, Strong SCHEMBL27649570 | 0.77 | KMT2A (0.55) | KMT2AMEN1MAPK1RAB9ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL31482133 | 0.76 | KMT2A (0.34) | KMT2AP2RX3P2RX2S1PR1S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200216415-A1 | MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2020-07-09 | — | — | US | disclosed |
| US-10562884-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2020-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10562884-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | MC3R, MC1R, MC2R | KMT2A 1341/4885P2RX3 335/4885P2RX2 301/4885 |
| US-20200216415-A1 | MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | MC3R, MC1R, MC2R | KMT2A 1341/4885P2RX3 335/4885P2RX2 301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.